Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis

Clinical Cardiology

Volumn 36, Issue 7, 2013, Pages 407-413

  Dorenkamp, Marc ^a   Boldt, Julia ^a   Leber, Alexander W ^b   Sohns, Christian ^c   Roser, Mattias ^a   Boldt, Leif Hendrik ^a   Haverkamp, Wilhelm ^a,e   Bonaventura, Klaus ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d KLINIKUM ERNST VON BERGMANN   (Germany)

^e UNIVERSITY OF POTSDAM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL;

ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; ERYTHROCYTE TRANSFUSION; GERMANY; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MEDICAL LITERATURE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

ANGIOPLASTY, BALLOON, CORONARY; CARDIAC CATHETERS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG CARRIERS; DRUG COSTS; DRUG-ELUTING STENTS; GERMANY; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MONTE CARLO METHOD; PACLITAXEL; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879846185     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22130     Document Type: Article

References (35)

1. Stone GW, Ellis SG, Cannon L, et al. TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005; 294: 1215-1223.
2. Tentzeris I, Jarai R, Farhan S, et al. Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. Clin Res Cardiol. 2011; 100: 191-200.
3. Abe M, Kimura T, Morimoto T, et al. j-Cypher Registry Investigators. Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: insights from the j-Cypher Registry. Circulation. 2010; 122: 42-51.
4. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010; 31: 2501-2555.
5. Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010; 56: 1897-1907.
6. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006; 48: 2584-2591.
7. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006; 355: 2113-2124.
8. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009; 119: 2986-2994.
9. Habara S, Mitsudo K, Kadota K, et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv. 2011; 4: 149-154.
10. Rittger H, Brachmann J, Sinha AM, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol. 2012; 59: 1377-1382.
11. Mehilli J, Byrne RA, Tiroch K, et al; ISAR-DESIRE 2 Investigators. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol. 2010; 55: 2710-2716.
12. Byrne R, Mehilli J, Cassese S, et al. Prospective, randomized trial of paclitaxel-eluting balloon versus paclitaxel-eluting stent versus balloon angioplasty for treatment of coronary restenosis in limus-eluting stents: the ISAR-DESIRE 3 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 3) study. Paper presented at: Transcatheter Cardiovascular Therapeutics (TCT) 2012; October 26, 2012; Miami, FL.
13. Bonaventura K, Leber AW, Sohns C, et al. Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. Clin Res Cardiol. 2012; 101: 573-584.
14. Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation. 2001; 104: 642-647.
15. Aldea GS, Mokadam NA, Melford R Jr, et al. Changing volumes, risk profiles, and outcomes of coronary artery bypass grafting and percutaneous coronary interventions. Ann Thorac Surg. 2009; 87: 1828-1838.
16. Hoffman SJ, Holmes DR Jr, Rabinstein AA, et al. Trends, predictors, and outcomes of cerebrovascular events related to percutaneous coronary intervention: a 16-year single-center experience. JACC Cardiovasc Interv. 2011; 4: 415-422.
17. Hannan EL, Racz M, Walford G,. Out-of-hospital deaths within 30 days following hospitalization where percutaneous coronary intervention was performed. Am J Cardiol. 2012; 109: 47-52.
18. Tarakji KG, Sabik JF III, Bhudia SK, et al. Temporal onset, risk factors, and outcomes associated with stroke after coronary artery bypass grafting. JAMA. 2011; 305: 381-390.
19. Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med. 2008; 358: 331-341.
20. van Domburg RT, Lemos PA, Takkenberg JJ, et al. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease. Eur Heart J. 2005; 26: 675-668.
21. Peters RJ, Mehta SR, Fox KA, et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003; 108: 1682-1687.
22. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170: 1433-1441.
23. Setoguchi S, Glynn RJ, Avorn J, et al. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol. 2008; 51: 1247-1254.
24. Wohrle J, Zadura M, Mobius-Winkler S, et al. SeQuent Please world wide registry: clinical results of SeQuent Please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol. 2012; 60: 1733-1738.
25. German Institute for the Hospital Remuneration System (InEK). G-DRG-System 2012: Fallpauschalen-Katalog 2012. http://www.g-drg.de/cms/G-DRG- System-2012/Fallpauschalen-Katalog/Fallpauschalen-Katalog-2012. Accessed December 4, 2012.
26. Rote Liste Service GmbH. Rote Liste 2012. Arzneimittelinformationen für Deutschland. Frankfurt am Main, Germany: Rote Liste Service GmbH; 2012.
27. Soskuty G., Innovationen in Diagnostik und Therapie: Zugang und Hürden im System. In:, Rebscher H, Kaufmann S, eds. Innovationsmanagement in Gesundheitssystemen. Heidelberg, Germany: Medhochzwei Verlag GmbH; 2010: 159-174.
28. Schweikert B, Hahmann H, Steinacker JM, et al. Intervention study shows outpatient cardiac rehabilitation to be economically at least as attractive as inpatient rehabilitation. Clin Res Cardiol. 2009; 98: 787-795.
29. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke. 2006; 37: 1179-1183.
30. Dorenkamp M, Bonaventura K, Leber AW, et al. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Eur Heart J. 2013; 34: 451-461.
31. Bonaventura K, Sonntag S, Kleber FX,. Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons. EuroIntervention. 2011; 7: K106-K111.
32. Kleber FX, Mathey DG, Rittger H, et al. German Drug-eluting Balloon Consensus Group. How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention. 2011; 7: K125-K128.
33. Tagliareni F, La Manna A, Saia F, et al. Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterisation laboratories. EuroIntervention. 2010; 5: 703-708.
34. Park K, Kim TE, Park KW, et al. Analysis of potential cost-savings after introduction of drug-eluting balloon angioplasty for in-stent restenosis or small vessel disease. Korean Circ J. 2011; 41: 705-711.
35. Scheller B, Clever YP, Kelsch B, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012; 5: 323-330.